These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 26238612)

  • 1. Novel quinazoline derivatives exhibit antitumor activity by inhibiting JAK2/STAT3.
    Qiao H; Zhao D; Shi H; Ren K; Li J; Li E
    Oncol Rep; 2015 Oct; 34(4):1875-82. PubMed ID: 26238612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physalin A exerts anti-tumor activity in non-small cell lung cancer cell lines by suppressing JAK/STAT3 signaling.
    Zhu F; Dai C; Fu Y; Loo JF; Xia D; Gao SP; Ma Z; Chen Z
    Oncotarget; 2016 Feb; 7(8):9462-76. PubMed ID: 26843613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
    Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
    Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Niclosamide overcomes acquired resistance to erlotinib through suppression of STAT3 in non-small cell lung cancer.
    Li R; Hu Z; Sun SY; Chen ZG; Owonikoko TK; Sica GL; Ramalingam SS; Curran WJ; Khuri FR; Deng X
    Mol Cancer Ther; 2013 Oct; 12(10):2200-12. PubMed ID: 23894143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A sesquiterpene lactone antrocin from Antrodia camphorata negatively modulates JAK2/STAT3 signaling via microRNA let-7c and induces apoptosis in lung cancer cells.
    Yeh CT; Huang WC; Rao YK; Ye M; Lee WH; Wang LS; Tzeng DT; Wu CH; Shieh YS; Huang CY; Chen YJ; Hsiao M; Wu AT; Yang Z; Tzeng YM
    Carcinogenesis; 2013 Dec; 34(12):2918-28. PubMed ID: 23880305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continuous exposure of non-small cell lung cancer cells with wild-type EGFR to an inhibitor of EGFR tyrosine kinase induces chemoresistance by activating STAT3.
    Tang J; Guo F; Du Y; Liu X; Qin Q; Liu X; Yin T; Jiang L; Wang Y
    Int J Oncol; 2015 May; 46(5):2083-95. PubMed ID: 25695284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of the JAK2/STAT3 signaling pathway exerts a therapeutic effect on osteosarcoma.
    Yan J; Wang Q; Zou K; Wang L; Schwartz EB; Fuchs JR; Zheng Z; Wu J
    Mol Med Rep; 2015 Jul; 12(1):498-502. PubMed ID: 25760445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Signal transducer and activator of transcription 3 as molecular therapy for non-small-cell lung cancer.
    Wang CY; Chao TT; Tai WT; Chang FY; Su WP; Chen YL; Chen PT; Weng CY; Yuan A; Shiau CW; Yu CJ; Chen KF
    J Thorac Oncol; 2014 Apr; 9(4):488-96. PubMed ID: 24736071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.
    Sette G; Salvati V; Mottolese M; Visca P; Gallo E; Fecchi K; Pilozzi E; Duranti E; Policicchio E; Tartaglia M; Milella M; De Maria R; Eramo A
    Cell Death Dis; 2015 Aug; 6(8):e1850. PubMed ID: 26247735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Constitutively activated STAT3 frequently coexpresses with epidermal growth factor receptor in high-grade gliomas and targeting STAT3 sensitizes them to Iressa and alkylators.
    Lo HW; Cao X; Zhu H; Ali-Osman F
    Clin Cancer Res; 2008 Oct; 14(19):6042-54. PubMed ID: 18829483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib.
    Morgillo F; Woo JK; Kim ES; Hong WK; Lee HY
    Cancer Res; 2006 Oct; 66(20):10100-11. PubMed ID: 17047074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor.
    Alvarez JV; Greulich H; Sellers WR; Meyerson M; Frank DA
    Cancer Res; 2006 Mar; 66(6):3162-8. PubMed ID: 16540667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Curcumin lowers erlotinib resistance in non-small cell lung carcinoma cells with mutated EGF receptor.
    Li S; Liu Z; Zhu F; Fan X; Wu X; Zhao H; Jiang L
    Oncol Res; 2013; 21(3):137-44. PubMed ID: 24512728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells.
    Martinelli E; Troiani T; Morgillo F; Rodolico G; Vitagliano D; Morelli MP; Tuccillo C; Vecchione L; Capasso A; Orditura M; De Vita F; Eckhardt SG; Santoro M; Berrino L; Ciardiello F
    Clin Cancer Res; 2010 Oct; 16(20):4990-5001. PubMed ID: 20810384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TPCA-1 is a direct dual inhibitor of STAT3 and NF-κB and regresses mutant EGFR-associated human non-small cell lung cancers.
    Nan J; Du Y; Chen X; Bai Q; Wang Y; Zhang X; Zhu N; Zhang J; Hou J; Wang Q; Yang J
    Mol Cancer Ther; 2014 Mar; 13(3):617-29. PubMed ID: 24401319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concomitant inactivation of the epidermal growth factor receptor, phosphatidylinositol 3-kinase/Akt and Janus tyrosine kinase 2/signal transducer and activator of transcription 3 signalling pathways in cardiotoxin III-treated A549 cells.
    Su JC; Lin KL; Chien CM; Chuang PW; Chang LS; Lin SR
    Clin Exp Pharmacol Physiol; 2010 Aug; 37(8):833-40. PubMed ID: 20456425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autophagy Inhibition Overcomes the Antagonistic Effect Between Gefitinib and Cisplatin in Epidermal Growth Factor Receptor Mutant Non--Small-Cell Lung Cancer Cells.
    Liu JT; Li WC; Gao S; Wang F; Li XQ; Yu HQ; Fan LL; Wei W; Wang H; Sun GP
    Clin Lung Cancer; 2015 Sep; 16(5):e55-66. PubMed ID: 25979647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring the mechanism of non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitor.
    Yu Y; Luo Y; Zheng Y; Zheng X; Li W; Yang L; Jiang J
    J Cancer Res Ther; 2016; 12(1):121-5. PubMed ID: 27072223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Silencing of SNX1 by siRNA stimulates the ligand-induced endocytosis of EGFR and increases EGFR phosphorylation in gefitinib-resistant human lung cancer cell lines.
    Nishimura Y; Takiguchi S; Yoshioka K; Nakabeppu Y; Itoh K
    Int J Oncol; 2012 Oct; 41(4):1520-30. PubMed ID: 22859339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crizotinib overcomes hepatocyte growth factor-mediated resistance to gefitinib in EGFR-mutant non-small-cell lung cancer cells.
    Chen X; Zhou JY; Zhao J; Chen JJ; Ma SN; Zhou JY
    Anticancer Drugs; 2013 Nov; 24(10):1039-46. PubMed ID: 23962905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.